- Baxdrostat shows significant reduction in systolic blood pressure in Phase III trial.
- Trial meets primary and all secondary endpoints in patients with uncontrolled or treatment-resistant hypertension.
- Baxdrostat well tolerated with a favorable safety profile.
Recent results from the BaxHTN Phase III trial have demonstrated that the drug baxdrostat, at doses of 2mg and 1mg, significantly and meaningfully reduced the mean seated systolic blood pressure (SBP) in comparison to a placebo over a 12-week period. This trial also successfully achieved all secondary endpoints. The study targeted patients with uncontrolled or treatment-resistant hypertension, who received either baxdrostat or a placebo in addition to standard care.
Baxdrostat, a potential first-in-class aldosterone synthase inhibitor, was generally well-tolerated and exhibited a favorable safety profile throughout the study. The drug targets aldosterone dysregulation, a significant contributor to hard-to-control hypertension. Approximately 50% of hypertensive patients in the US have difficulty maintaining blood pressure control despite being on multiple medications, making this development particularly noteworthy.
The data from the BaxHTN Phase III trial will be presented in a late-breaking session at the European Society of Cardiology (ESC) Congress in August 2025. Baxdrostat is currently under investigation for use as a monotherapy for hypertension and primary aldosteronism, as well as in combination with dapagliflozin for chronic kidney disease and prevention of heart failure in high-risk patients. Baxdrostat was acquired by AstraZeneca (AZN, Financial) through the purchase of CinCor Pharma, Inc. in February 2023.
This significant progress in cardiovascular treatment provides compelling evidence of baxdrostat’s potential to address a critical unmet need, bringing a novel mechanism to a field that has seen limited innovation over the past two decades.
